Science Letter
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Science Letter
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Myeloid Leukemia
Autotransplantation increases 3-year survival for AML patients in first or second remission
April 21st, 2006
Autotransplantation increases the 3-year survival for acute myeloid leukemia patients in first or second remission. "Most acute myeloid leukemia (AML) patients lack human leukocyte antigen-identical sibling donors for transplantation. Autotransplants and unrelated donor (URD) transplants are therapeutic options," researchers in the United States report. "To compare autologous versus URD transplantation for AML in first (CR1) or second complete remission (CR2), we studied the outcomes of 668 autotransplants were compared with 476 URD transplants reported to the Center for International Blood and Marrow Transplant Research. ...
Source: Science Letter (2006-04-21)
|
